Terns Pharmaceuticals

About Terns Pharmaceuticals

Terns Pharmaceuticals is dedicated to elevating human health by developing superior, life-changing small molecule therapies for indications with serious unmet medical needs. They focus on de-risked, clinically validated mechanisms of action and aim to accelerate the development of innovative treatments.

Products & Services

TERN-701:A therapy targeting chronic myeloid leukemia (CML), currently in Phase 1 with data expected in Q4 2025.

TERN-601:A therapy targeting obesity, part of the clinical-stage pipeline.

Specialties

Oncology Metabolic Diseases Small Molecule Therapies Clinical-Stage Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 747500000 MR: - FA: $747.5 million FAN: 747500000	D: 2025-12-11 FD: 2025-12-11	6 investors
2	RT: Public Offering T: - FT: Public Offering	A: 400000000 MR: - FA: $400 million FAN: 400000000	D: 2025-12-09 FD: 2025-12-09	6 investors
3	RT: Public Offering T: - FT: Public Offering	A: 650000000 MR: - FA: $650 million FAN: 650000000	D: 2025-12-09 FD: 2025-12-09	6 investors
4	RT: Public Offering T: - FT: Public Offering	A: 172700000 MR: - FA: approximately $172.7 million FAN: 172700000	D: 2024-09-12 FD: 2024-09-12	6 investors
5	RT: Public Offering T: - FT: Public Offering	A: 150150000 MR: - FA: $150.15 million FAN: 150150000	D: 2024-09-10 FD: 2024-09-10	6 investors

Public Offering Latest

2025-12-11

$747.5M

6 investors (Pro only)

Public Offering 2025-12-09

$400.0M

Public Offering 2025-12-09

$650.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News